title: [Autosomal recessive cerebellar ataxias. Their classification, genetic features and pathophysiology].
abstract: BACKGROUND
  Autosomal recessive cerebellar ataxias (ARCA) are a heterogeneous group of rare neurological disorders involving both central and peripheral nervous system, and in some case other systems and organs. They use to have early onset before the age of 20. Based on pathogenic mechanisms five main types may be distinguished: congenital (developmental disorder), mitochondrial ataxias, ataxias associated with metabolic disorders, ataxias with a DNA repair defect, and degenerative ataxia with unknown pathogenesis. The most frequent in Caucasian population are Friedreich ataxia and ataxia-telangiectasia. Other forms are much less common, and include abetaliproteinemia, ataxia with vitamin E deficiency (AVED), ataxia with oculomotor apraxia types 1 (AOA1) and 2 (AOA2), early onset cerebellar ataxia with retained reflexes, Charlevoix-Saguenay spastic ataxia, and Joubert syndrome. The prevalence of ARCA has been estimated to 7 in 100,000 inhabitants. These diseases are due to mutations in specific genes, some of which and its encoded proteins have been identified, such as FRDA (frataxin) in Friedreich ataxia, APTX (aprataxin) in AOA1, alphaTTP (alpha-tocopherol transfer protein) in AVED, and STX (senataxin) in AOA2. Due to autosomal recessive inheritance, previous familial history of affected individuals unlikely.
  
  
  CONCLUSIONS
  Most of these cerebellar ataxias have no specific treatment with exception of the ataxia associated with deficiency coenzyme Q10 and abetalipoproteinemia. Clinical diagnosis must be confirmed by ancillary tests such as neuroimaging (magnetic resonance, scanning), electrophysiological examination, and mutation analysis when the causative gene has been identified. Correct clinical and genetic diagnosis is important for appropriate prognosis and genetic counseling and, in some instances, pharmacological treatment.
authors.affiliation: Laboratorio de Genética y Medicina Molecular, Instituto de Biomedicina, CSIC, Valencia, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Espinós-Armero
authors.forename: P
authors.initials: P
authors.lastname: González-Cabo
authors.forename: F
authors.initials: F
authors.lastname: Palau-Martínez
mesh_terms: D017668:Age of Onset; D000818:Animals; D002524:Cerebellar Ataxia / Q000145:classification / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D020271:Heredodegenerative Disorders, Nervous System / Q000145:classification / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D033862:Iron-Binding Proteins / Q000235:genetics / Q000378:metabolism; D025202:Molecular Diagnostic Techniques; D009154:Mutation; D000096923:Frataxin
chemical_list: D033862:Iron-Binding Proteins; D000096923:Frataxin